Hutchinson-Gilford progeria syndrome (HGPS) is a rare genetic disorder in which children age at an accelerated pace because of a mutation in the LMNA gene and the buildup of a defective protein called progerin. The p53 protein is a central regulator of cellular senescence and tumor defense, but its excessive activity accelerates aging. Earlier work in cell cultures showed that the Δ133p53α isoform, which lacks the first 132 amino acids, acts as a dominant-negative inhibitor of p53: it suppresses senescence genes (such as p21) while preserving the activity of DNA repair genes. It was unclear, however, whether this mechanism works in a whole organism. The study sits somewhat apart from neighboring research: nearby are papers on cellular senescence, prostate cancer and dark energy, but there are no direct predecessors on Δ133p53α in vivo.
The researchers created transgenic mice carrying a CAG-LSL-Δ133p53α allele at the ROSA26 locus, which is activated by Cre recombinase after tamoxifen injection. These mice were crossed with the LmnaG609G progeria model, which carries the human mutation. Expression of Δ133p53α was induced at 5–6 weeks of age. Four groups of mice were then compared: with induced Δ133p53α expression (group 1), without induction (group 2), with Cre but without the transgene (group 3), and with neither (group 4). The team assessed cellular senescence (p21, p16, SA-β-gal), DNA damage (γ-H2AX), inflammation (IL-6), aortic and skin histology, kyphosis by CT, lifespan, and the heart and kidney transcriptome by RNA-seq. They also analyzed GTEx data on Δ133p53α and CDKN1A expression in human skin.
In progeria mice, Δ133p53α expression lowered levels of p21Waf1/Cip1, p16Ink4a and γ-H2AX in the aorta, skin and skeletal muscle, and reduced serum IL-6 to wild-type levels. In the aorta, smooth muscle cell numbers and media thickness were restored; in the skin, so were dermis thickness and Sox9 expression in hair follicles. Median lifespan rose from 349 to 387 days (an 11% gain, P=0.0379) compared with group 3, and from 358 to 387 days (P=0.0312) compared with group 4. Kyphosis developed less often and later. RNA-seq revealed suppression of the p53 pathway and inflammatory pathways, activation of oxidative phosphorylation in the heart and kidneys, and of glycolysis in the kidneys. In wild-type mice aged 26–28 months, Δ133p53α increased smooth muscle cell numbers in the aorta and the thickness of dermal white fat, and lowered IL-6. In human skin, Δ133p53α levels decline with age while CDKN1A rises; the two are inversely correlated.
The work is the first to prove that Δ133p53α works in vivo: it slows aging and extends life without raising tumor risk. Unlike neighboring studies that examined cellular senescence in vitro or individual aspects of progeria, this one achieved a systemic effect at the level of the whole organism. It supports the hypothesis that selectively inhibiting p53-dependent aging may be a safe strategy against age-related diseases. What is more, Δ133p53α was shown to act independently of progerin levels, which opens the door to combination therapy with drugs targeting progerin itself.
The field could move toward pharmacological activation of Δ133p53α: two compounds that raise its levels in human cells have already been found. The induction protocol might be optimized (earlier or tissue-specific) to strengthen the effect. Studying Δ133p53α in other models of age-related disease, such as neurodegeneration or idiopathic pulmonary fibrosis, also looks promising.
The results could influence the development of progeria therapy and, in time, strategies for slowing natural aging in humans. They also provide a new tool for research on cellular senescence and the role of p53 in ageing.
Next steps include optimizing the timing and methods of Δ133p53α induction, testing the effect in a homozygous progeria model, and developing pharmacological activators of this isoform for preclinical trials.
The work connects to a central problem in gerontology: how to separate the beneficial and harmful functions of p53. It shows that partial and selective inhibition of p53 through its natural isoform can slow aging without carcinogenesis, something previously considered very hard to achieve. It also touches on the question of which downstream p53 targets are responsible for aging, and opens the way to finer modulation of the p53 pathway.
Δ133p53α got its name because it starts at the 133rd amino acid residue of p53, while the letter Δ (delta) means a deletion of the first 132 amino acids. This isoform occurs naturally in human cells, and its levels fall with age.
In Aldous Huxley's novel Brave New World, people age more slowly thanks to genetic manipulation. Work on Δ133p53α is a step in the same direction, but without the dystopian undertone: the goal is not immortality but a longer healthy life.
Not published on arXiv. Here are its page, the PDF and the formalization: you can check it yourself, not only read our account.